Conference call and webcast on Friday, November 8 at 2:30 pm CET/8:30 am ET.
- TRYbeCA1, Phase 3 trial of eryaspase in second line pancreatic cancer:
- positive safety review by independent data monitoring committee
- opened for patient enrollment in the United States
- first U.S. clinical sites activated
- Princeton manufacturing facility ready for production of clinical batches
- Cash position of €81.9 million ($89.2 million) at the end of September